Today: 21 May 2026
Browse Category

NYSE:PFE 6 October 2025 - 7 November 2025

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer (PFE) Stock Today — Nov 7, 2025: Metsera Bidding War Intensifies, Dividend Record Date, and What’s Moving the Share Price

Pfizer shares fell 2.3% to $24.28 amid heavy trading as a Delaware judge allowed Metsera to exit its deal with Pfizer, intensifying the takeover battle with Novo Nordisk. Pfizer is reportedly considering a higher bid ahead of Metsera’s Nov. 13 shareholder vote. The company marked its dividend record date today for a $0.43 payout. Earlier this week, Pfizer raised its 2025 EPS guidance after beating Q3 estimates.
7 November 2025
····
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

A Delaware court denied Pfizer’s request to block Metsera from ending their merger deal in favor of Novo Nordisk’s higher bid. Pfizer plans to raise its offer after Novo’s proposal reached up to $10 billion. FTC staff warned Novo’s bid structure could violate pre-merger rules. Pfizer shares traded near $24.61 midday Thursday.
6 November 2025
····
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer closed at $24.45 on Nov. 5, 2025, with a market cap near $138 billion, more than 60% below its pandemic-era peak. Q3 revenue fell 6% to about $16.7 billion, while adjusted earnings beat forecasts at $0.87 per share. COVID-19 product sales continued to drop sharply. Pfizer is in a bidding war with Novo Nordisk for obesity drug developer Metsera.
5 November 2025
··
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera shares jumped nearly 20% to $73.29 on November 4, 2025, hitting a 52-week high after Novo Nordisk raised its takeover offer to $86.20 per share, topping Pfizer’s $70 bid. Metsera’s board called Novo’s proposal “Superior.” A Delaware judge declined to halt the bidding war, fueling further gains. Pfizer has until midweek to counter Novo’s offer.
4 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer shares traded near $24.60 on Nov. 4, 2025, down about 8–9% year-to-date and over 60% from their 2021 peak. Q3 adjusted earnings beat forecasts at $0.87 per share, but revenue missed slightly at $16.65 billion. Pfizer raised its full-year profit outlook and reaffirmed revenue guidance. The company is locked in a takeover battle with Novo Nordisk for obesity drug developer Metsera.
4 November 2025
·····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk raised its offer for Metsera to about $10 billion, topping Pfizer’s $8.1 billion bid. Metsera’s board labeled Novo’s bid “superior,” triggering a two-day window for Pfizer to respond. Pfizer has filed lawsuits in Delaware and federal court to block Novo’s challenge. Shares in Metsera jumped 20% after the news, while Novo’s stock slipped.
4 November 2025
···
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer reported Q3 2025 adjusted earnings of $0.87 per share, beating estimates, with revenue at $16.65–$16.7 billion. The company raised its full-year profit outlook to $3.00–$3.15 EPS. Sales of COVID products plunged, but demand for Eliquis and Vyndaqel rose. Pfizer sued Novo Nordisk over a $7.3 billion bid for obesity drugmaker Metsera; a court hearing is set for Nov. 4.
4 November 2025
···
Nasdaq Stumbles as Fed Jitters Mount, Intel Soars, Tariffs Rattle Tech Markets

AI Rally Hits Speed Bump as Futures Fall – Key Facts Before the Nov. 4 Market Open

U.S. stock futures fell sharply early Tuesday, with Nasdaq 100 futures down 1.2% and S&P 500 off 0.9%. The drop follows a stalled tech rally and overnight losses in Europe and Asia. Key economic data releases are delayed by a government shutdown, adding to market uncertainty. Palantir shares slid over 4% despite strong earnings, while Bitcoin dropped 3% to around $104,000.
4 November 2025
···········
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer shares traded at $24.65 on Nov. 3, 2025, down about 3% year-to-date and over 50% from pandemic highs. The company reports Q3 results Nov. 4, with analysts expecting $16.6 billion in revenue and $0.66 EPS. Pfizer completed a $43 billion Seagen acquisition and is in a bidding war with Novo Nordisk over Metsera. The quarterly dividend is $0.43 per share, yielding around 7%.
3 November 2025
··
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer shares closed at $24.65 on Oct. 31, 2025, rebounding from September lows after a White House drug pricing deal but still near multi-year lows. The company is suing Novo Nordisk over an $8.5 billion bid for obesity drugmaker Metsera, which undercut Pfizer’s own $7.3 billion offer. Investors await Pfizer’s Q3 earnings on Nov. 4 as the firm faces a sharp drop in COVID-related sales.
2 November 2025
·
Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer shares surged 15% in late September after announcing a Medicaid drug price deal with the Trump administration, but fell back to $24.65 by Oct. 31. The company will report Q3 2025 earnings on Nov. 4, with analysts expecting a year-over-year drop in profit. Pfizer agreed to buy obesity drug developer Metsera for up to $7.3 billion as it seeks new growth beyond COVID-19 products.
1 November 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Novo Nordisk made an unsolicited $8.5 billion bid for Metsera, topping Pfizer’s earlier $7.3 billion deal. Metsera’s board called Novo’s offer “superior,” triggering a four-day window for Pfizer to respond. Metsera shares jumped over 18% on the news, while Novo’s stock fell 3%. Pfizer criticized Novo’s move as “reckless,” warning it could suppress competition.
31 October 2025
····
Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer shares traded near $24.20 on Oct. 30, 2025, flat for the week and close to the low end of their 52-week range. The stock surged 15% in late September after Pfizer agreed to cut Medicaid drug prices and announced a $7.3 billion deal to acquire obesity-drug maker Metsera. Rival Novo Nordisk countered with a higher bid for Metsera. Q3 earnings are due Nov. 4, with analysts expecting a sharp year-over-year decline.
30 October 2025
··
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Novo Nordisk launched a hostile bid for Metsera on Oct. 30, 2025, offering up to $9 billion and topping Pfizer’s earlier $7.3 billion deal. Metsera shares jumped about 19% in premarket trading. The board called Novo’s offer “superior,” giving Pfizer four days to respond. A law firm began investigating whether the original Pfizer deal was fair to shareholders.
30 October 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk launched an $8.5 billion unsolicited bid for obesity drugmaker Metsera, topping Pfizer’s $7.3 billion agreed deal. Novo’s offer values Metsera at $56.50 per share in cash plus up to $21.25 in milestone payments. Metsera shares jumped 18% premarket, while Novo’s stock fell 3%. Pfizer called Novo’s bid “reckless” and warned it could harm competition.
30 October 2025
····
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

Pfizer shares traded near $24.76 on Oct. 24, up about 9% from their 52-week low but still down for the year. The stock jumped over 6% in late September after Pfizer reached a deal with the Trump administration to cut Medicaid drug prices, easing regulatory risk. Pfizer reports Q3 results Nov. 4, with analysts expecting lower earnings due to falling COVID product sales.
27 October 2025
··
U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Wall Street Explodes: Dow Jones Jumps 400 Points as Inflation Cools – Tech Stocks Lead, Fed Cuts Expected

U.S. stocks closed at record highs Friday, with the Dow up 400 points and the S&P 500 and Nasdaq also reaching new peaks. Tech and chip stocks led gains—AMD surged 6.5%, Nvidia 4.2%. September inflation rose just 0.3%, below forecasts, boosting bets on a Fed rate cut at the Oct. 29 meeting. Energy and industrial shares lagged, while a partial government shutdown continued.
24 October 2025
·············
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer shares surged 15% from $23.6 to $27.2 after announcing a Medicaid pricing deal with the Trump administration and agreeing to buy obesity drug developer Metsera for up to $7.3 billion. Q2 revenue rose 10% to $14.7 billion, beating estimates. Pfizer trimmed its dividend but still yields 6–7%. Analysts raised price targets to $29–30, citing the pricing pact and new drug prospects.
19 October 2025
·
Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

The Nasdaq closed at 22,679.98 Friday, up 117 points, capping a volatile week near record highs. Nvidia shares retreated after hitting records, while AMD jumped 34% on an OpenAI chip deal. The KBW Regional Bank Index rebounded after sharp losses as banks addressed loan and fraud concerns. The VIX spiked to a six-month high before easing, with traders bracing for volatility ahead of major tech earnings and a delayed U.S. inflation report.
18 October 2025
·········
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Pfizer shares surged 15% in late September 2025, jumping from $23.60 to $27.20 after a drug-pricing deal with the Trump administration slashed Medicaid prices and a $7.3 billion acquisition of obesity-drug maker Metsera. The stock hovered near $27–$28 as of Oct. 6, near its 52-week high. Pfizer’s dividend yield rose above 7% after earlier declines. Q2 revenue climbed 10% year-over-year to $14.7 billion.
6 October 2025
·
1 … 7 8 9 10

Stock Market Today

  • IonQ Soars 755% Revenue Growth, Expands into Satellite Networking
    May 21, 2026, 7:35 AM EDT. IonQ reported a 755% year-over-year revenue increase after shifting to a full-stack quantum computing model. The firm also announced expansion into satellite networking, signaling broader applications for its technology. This growth and diversification led to a rating upgrade, positioning IonQ as a standout quantum stock with notable upside potential and distinct risks.

Latest articles

Quantum Stocks Surge on $2 Billion Play; IonQ Faces Next Hurdle

Quantum Stocks Surge on $2 Billion Play; IonQ Faces Next Hurdle

21 May 2026
IonQ shares jumped 8% in premarket trading Thursday to $52.47 after the U.S. announced $2 billion in quantum-computing grants, though IonQ was not among the recipients. The company recently reported first-quarter revenue of $64.7 million, up 755% year-over-year, and raised its 2026 revenue outlook to $260–$270 million. SkyWater shareholders approved IonQ’s merger, pending regulatory approval.
Rigetti Shares Rally on U.S. Quantum Funding as Debate Over Value Returns

Rigetti Shares Rally on U.S. Quantum Funding as Debate Over Value Returns

21 May 2026
Rigetti Computing shares jumped 13.2% in premarket trading Thursday after reports the Trump administration will award $2 billion in grants to nine quantum-computing firms, including $100 million for Rigetti. The company reported Q1 revenue of $4.4 million and an operating loss of $26 million. Shares closed Wednesday at $16.88, quoted at $19.10 before the market opened.
VIDA Global Stock Draws Attention After AI Agent IPO

VIDA Global Stock Draws Attention After AI Agent IPO

21 May 2026
VIDA Global shares jumped 81.2% to close at $4.15 Wednesday, then traded at $4.97 pre-market Thursday after volatile early sessions on NYSE American. Founder and CEO Lyle Pratt bought 187,500 shares at the $4 IPO price, SEC filings showed. The company raised $15 million in its IPO last week, selling 3.75 million shares. VIDA reported 2025 revenue of $551,383 and a net loss of $2.9 million.
Go toTop